Rapid Dose Therapeutics Corp.
RDTCF
$0.15
$0.0436.36%
OTC PK
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.24% | 90.13% | 225.80% | 112.90% | 42.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.24% | 90.13% | 225.80% | 112.90% | 42.15% |
| Cost of Revenue | 57.51% | 166.38% | 267.13% | 119.87% | 67.32% |
| Gross Profit | 14.57% | 47.88% | 191.15% | 107.28% | 30.87% |
| SG&A Expenses | -31.19% | -31.41% | 94.68% | 76.67% | 89.25% |
| Depreciation & Amortization | 168.66% | 56.84% | -72.97% | -68.72% | -65.11% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.63% | -7.74% | 39.82% | 46.47% | 62.65% |
| Operating Income | 36.81% | 48.73% | -8.89% | -26.93% | -78.10% |
| Income Before Tax | 25.06% | 44.19% | 23.13% | -38.03% | -46.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.06% | 44.19% | 23.13% | -38.03% | -46.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.06% | 44.19% | 23.13% | -38.03% | -46.48% |
| EBIT | 36.81% | 48.73% | -8.89% | -26.93% | -78.10% |
| EBITDA | 37.93% | 49.99% | -16.95% | -49.68% | -139.25% |
| EPS Basic | -12.31% | 48.68% | 33.09% | -14.29% | -22.64% |
| Normalized Basic EPS | -12.20% | 48.94% | 7.94% | -16.28% | -24.24% |
| EPS Diluted | -12.31% | 48.68% | 33.09% | -14.29% | -22.64% |
| Normalized Diluted EPS | -12.20% | 48.94% | 7.94% | -16.28% | -24.24% |
| Average Basic Shares Outstanding | -32.95% | 7.90% | 14.55% | 20.14% | 18.87% |
| Average Diluted Shares Outstanding | -32.95% | 7.90% | 14.55% | 20.14% | 18.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |